Bacillus amyloliquefaciens levan and its silver nanoparticles with antimicrobial properties

23Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this study, the exopolysaccharide from Bacillus amyloliquefaciens PB6 was purified and identified as levan. To explore the application of this levan in nanotechnology, its silver nanoparticles (AgNPs) were prepared in a simple and green method. Transmission electron microscopy analysis revealed that the size of the synthesised AgNPs was in the range of 19.47 ± 2.45 nm. X-ray powder diffraction analysis confirmed the face-centred cubic crystalline structure of metallic silver. Moreover, the AgNPs at the concentration of 0–12 μg/mL exhibited a significant inhibitive effect on Staphylococcus aureus and Escherichia coli. Tested by tetrazolium-based colourimetric assay, the viability of RAW 264.7 cells was higher than 75% in the presence of 20 μg/mL AgNPs. The results not only proved the feasibility of producing levan from B. amyloliquefaciens with high safety and a high yield, but also demonstrated the simple and cost-efficient approach of AgNPs synthesis as potential antibacterial agents from levan.

Cite

CITATION STYLE

APA

Zhang, J., Yue, X., Zeng, Y., Hua, E., Wang, M., & Sun, Y. (2018). Bacillus amyloliquefaciens levan and its silver nanoparticles with antimicrobial properties. Biotechnology and Biotechnological Equipment, 32(6), 1583–1589. https://doi.org/10.1080/13102818.2018.1523690

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free